Arcutis Biotherapeutics Inc (ARQT) — Cash Flow-to-Debt Ratio
Arcutis Biotherapeutics Inc (ARQT) has a Cash Flow-to-Debt Ratio of 0.01x as of March 2026, meaning its operating cash flow of $2.24 Million could theoretically repay 0% of its total liabilities ($270.36 Million) in one year. Check ARQT capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Arcutis Biotherapeutics Inc Cash Flow-to-Debt Ratio (2017–2025)
Historical debt coverage capacity for Arcutis Biotherapeutics Inc across 9 annual periods. Also explore ARQT total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Arcutis Biotherapeutics Inc (2017–2025)
Year-by-year debt coverage analysis for Arcutis Biotherapeutics Inc. For market capitalisation and broader financial context, see Arcutis Biotherapeutics Inc market cap and net worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -0.02x | $-5.62 Million | $243.49 Million | ▲ +96.1% |
| 2024 | -0.59x | $-112.16 Million | $191.35 Million | ▲ +40.0% |
| 2023 | -0.98x | $-247.06 Million | $252.70 Million | ▲ +9.1% |
| 2022 | -1.08x | $-257.71 Million | $239.69 Million | ▲ +32.0% |
| 2021 | -1.58x | $-174.63 Million | $110.47 Million | ▲ +61.3% |
| 2020 | -4.09x | $-113.03 Million | $27.65 Million | ▲ +47.0% |
| 2019 | -7.72x | $-42.84 Million | $5.55 Million | ▼ -4014.5% |
| 2018 | -0.19x | $-14.09 Million | $75.08 Million | ▲ +56.2% |
| 2017 | -0.43x | $-3.77 Million | $8.81 Million | — |